Ravasio R, Cranmer H, Kearns I, Viti R, Corinti S. Cost-utility analysis of brigatinib compared to alectinib in the treatment of ALK-positive NSCLC in patients previously not treated with an ALK inhibitor. AboutOpen [Internet]. 2022 Oct. 24 [cited 2024 Nov. 21];9(1):92-104. Available from: https://journals.aboutscience.eu/index.php/aboutopen/article/view/2450